

Financial news for QURE dated on 2020-05-14: uniQure Highlights Presentations For ASGCT Meeting

Financial news for QURE dated on 2020-05-13: Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C. and Los Angeles County.

Financial news for QURE dated on 2020-04-29: uniQure Q1 EPS \$(0.630) Up From \$(0.740) YoY

Financial news for QURE dated on 2020-04-24: uniQure Shares Volatile On Uptick In Volume; Hearing Cantor Fitzgerald Out With Positive Comments On Name

Financial news for QURE dated on 2020-04-07: Shares of several healthcare companies are trading higher amid optimism that coronavirus cases in Asia are potentially easing. Global slowing cases could raise hopes of a sooner return to spending and economic activity. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic.

Financial news for QURE dated on 2020-03-26: uniQure Reports Achievement Of Target Patient Dosing In HOPE-B Trial Of AMT-061 For Hemophilia B

Financial news for QURE dated on 2020-03-09: Shares of several healthcare companies are trading lower. Movement appears market-related as markets continue to dip amid the global coronavirus outbreak and OPEC failing to reach production agreement.

Financial news for QURE dated on 2020-03-06: Shares of several healthcare companies are trading lower. Movement appears market related as markets continue to dip amid the global coronavirus outbreak.

Financial news for QURE dated on 2020-03-03: Chardan Capital Maintains Buy on uniQure, Lowers Price Target to \$105

Financial news for QURE dated on 2020-03-02: uniQure And Gen-X Enter Research Collaboration And License Agreement For The Development Of Novel Synthetic Promoters

Financial news for QURE dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for QURE dated on 2020-01-23: Cantor Fitzgerald Maintains Overweight on uniQure, Raises Price Target to \$96

Financial news for QURE dated on 2019-12-24: 10 Biotech M&A Targets Under The Scanner For 2020

Financial news for QURE dated on 2019-12-23: A Perspective On Biopharma's Record M&A Run In 2019

Financial news for QURE dated on 2019-12-18: uniQure Option Alert: Jan 17 \$80 Calls Sweep (4) above Ask!: 575 @ \$2.75 vs 1546 OI; Ref=\$70.45

Financial news for QURE dated on 2019-12-10: 10 Biggest Price Target Changes For Tuesday

Financial news for QURE dated on 2019-12-10: Mizuho Reiterates Buy on uniQure, Raises Price Target to \$90

Financial news for QURE dated on 2019-12-08: uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B at ASH 2019

Financial news for QURE dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for QURE dated on 2019-12-04: 63 Biggest Movers From Yesterday

Financial news for QURE dated on 2019-12-03: 40 Stocks Moving In Tuesday's Mid-Day Session

Financial news for QURE dated on 2019-12-03: The Gene Therapy Names Moving On The Audentes Buyout Deal

Financial news for QURE dated on 2019-12-03: UniQure shares are trading higher following the acquisition of gene therapy peer Audentes Therapeutics by Astellas.

Financial news for QURE dated on 2019-12-03: Benzinga's Top Upgrades, Downgrades For

December 3, 2019

Financial news for QURE dated on 2019-12-03: UniQure NV shares are trading higher after analysts from Goldman Sachs and Cowen & Co initiated coverage on the company's stock with bullish ratings.

Financial news for QURE dated on 2019-12-03: 19 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for QURE dated on 2019-12-03: 22 Stocks Moving in Tuesday's Pre-Market Session

Financial news for QURE dated on 2019-12-03: Cowen & Co. Initiates Coverage On uniQure with Outperform Rating

Financial news for QURE dated on 2019-12-03: Goldman Sachs Initiates Coverage On uniQure with Buy Rating, Announces \$98 Price Target

Financial news for QURE dated on 2019-11-05: Benzinga's Top Upgrades, Downgrades For November 5, 2019

Financial news for QURE dated on 2019-11-05: uniQure Announces The Allowance Of New Patent Providing Further Protection Of The Padua And Padua-Related Variants Of Factor IX In Gene Therapy

Financial news for QURE dated on 2019-11-05: Credit Suisse Initiates Coverage On uniQure with Outperform Rating, Announces \$76 Price Target

Financial news for QURE dated on 2019-10-31: uniQure Highlights Publication Of Interim Data From Phase IIb Clinical Trial Of Etranacogene Dezaparvovec

Financial news for QURE dated on 2019-10-11: Benzinga's Top Upgrades, Downgrades For October 11, 2019

Financial news for QURE dated on 2019-10-11: Stifel Nicolaus Initiates Coverage On uniQure with Buy Rating, Announces \$79 Price Target

Financial news for QURE dated on 2019-09-25: Benzinga's Top Upgrades, Downgrades For September 25, 2019

Financial news for QURE dated on 2019-09-25: Bernstein Initiates Coverage On uniQure with Outperform Rating, Announces \$73 Price Target

Financial news for QURE dated on 2019-09-12: Mizuho Initiates Coverage On uniQure with Buy Rating, Announces \$67 Price Target

Financial news for QURE dated on 2019-09-06: 16 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for QURE dated on 2019-09-06: 86 Biggest Movers From Yesterday

Financial news for QURE dated on 2019-09-06: uniQure Prices 4.9M Share Public Offering @\$46/Share

Financial news for QURE dated on 2019-09-05: 55 Stocks Moving In Thursday's Mid-Day Session

Financial news for QURE dated on 2019-09-05: UniQure shares are trading lower after the company reported a \$200 million common stock offering.

Financial news for QURE dated on 2019-09-05: The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug

Financial news for QURE dated on 2019-09-04: UniQure shares are trading lower after the company reported a \$200 million common stock offering.

Financial news for QURE dated on 2019-09-04: uniQure Reports \$200M Common Stock Offering

Financial news for QURE dated on 2019-09-03: uniQure Achieves Planned Enrollment In HOPE-B Pivotal Trial Of AMT-061 In Patients With Hemophilia B

Financial news for QURE dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for QURE dated on 2019-07-30: Benzinga's Top Upgrades, Downgrades For July 30, 2019

Financial news for QURE dated on 2019-07-30: Guggenheim Downgrades uniQure to Neutral

Financial news for QURE dated on 2019-07-29: uniQure Q2 EPS \$(0.83) Misses \$(0.75) Estimate, Sales \$2.47M Beat \$1.46M Estimate

Financial news for QURE dated on 2019-07-15: uniQure Option Alert: Jan 17 \$70 Calls Sweep (2) near the Ask: 600 @ \$14.351 vs 19 OI; Earnings 8/7 Before Open [est] Ref=\$68.48

Financial news for QURE dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for QURE dated on 2019-07-06: uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061; Clinical Benefit and Tolerability Maintained in All Patients Through Up to 3.5 Years of Follow-up

Financial news for QURE dated on 2019-07-05: The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight

Financial news for QURE dated on 2019-06-29: The Week Ahead In Biotech: Pending Clinical Readouts In Focus

Financial news for QURE dated on 2019-06-25: 60 Biggest Movers From Yesterday

Financial news for QURE dated on 2019-06-24: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for QURE dated on 2019-06-18: The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

Financial news for QURE dated on 2019-06-18: 60 Biggest Movers From Yesterday

Financial news for QURE dated on 2019-06-17: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for QURE dated on 2019-06-17: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for QURE dated on 2019-06-17: Report: uniQure Could Put Itself Up For Sale

Financial news for QURE dated on 2019-06-17: UniQure shares are trading higher following a media report that the company is exploring strategic options, including a potential sale.

Financial news for QURE dated on 2019-06-17: A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Economic Data

Financial news for QURE dated on 2019-06-17: 5 Stocks To Watch For June 17, 2019

Financial news for QURE dated on 2019-06-17: uniQure Shares Rise 9% Premarket to \$79 Following Bloomberg Report Company Exploring Options Including Potential Sale

Financial news for QURE dated on 2019-06-16: Gene-Therapy Firm UniQure Explores Options Including Sale

Financial news for QURE dated on 2019-06-12: 66 Biggest Movers From Yesterday

Financial news for QURE dated on 2019-06-11: uniQure shares are trading lower despite no clear catalyst to justify price action. One analyst suggested downside may be due to profit taking following recent strength.

Financial news for QURE dated on 2019-06-11: Janney Reiterates Buy On uniQure As Firm 'Would Be Buyers On Today's Weakness' As Firm Believes Co. Should Have 'the first FDA approval for an AAV gene therapy for hemophilia B, 2) the first AAV gene therapy program in the clinic for Huntingon's'

Financial news for QURE dated on 2019-06-11: 48 Stocks Moving In Tuesday's Mid-Day Session

Financial news for QURE dated on 2019-06-06: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

Financial news for QURE dated on 2019-06-05: 4 Momentum Stocks To Watch

Financial news for QURE dated on 2019-06-05: The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache

Financial news for QURE dated on 2019-06-04: Adam Feuerstein Tweet: I call b\*\*\*\*\*t. Do you people know where Goldman holds this conference? No one cancels for a schedule conflict

Financial news for QURE dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for QURE dated on 2019-06-03: Shares of several biotechs are trading higher in sympathy with Amgen after the company presented the first clinical data evaluating a KRASG12C inhibitor, AMG 510, at ASCO 2019.

Financial news for QURE dated on 2019-05-22: Shares of several companies in the healthcare sector are trading lower. Not seeing any news to justify this price action.

Financial news for QURE dated on 2019-05-22: uniQure Reports Was Issued 2 New Patents Covering AMT-130

Financial news for QURE dated on 2019-05-10: uniQure shares trading higher following news the company presented data from a Phase IIb study of AMT-061 in patients with hemophilia B.

Financial news for QURE dated on 2019-05-10: uniQure Highlights Presentation Of Data From Phase IIb Study Of AMT-061 In Patients With Hemophilia B

Financial news for QURE dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for QURE dated on 2019-05-02: Uniqure Will Present Today New Preclinical Data On Its Gene Therapy Candidates Amt-180 For The Treatment Of Hemophilia A And Amt-190 For The Treatment Of Fabry Disease

Financial news for QURE dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for QURE dated on 2019-04-29: uniQure Q1 EPS \$(0.74) Misses \$(0.71) Estimate, Sales \$1.136M Miss \$2.05M Estimate

Financial news for QURE dated on 2019-04-12: PiperJaffray Initiates Coverage On uniQure with Overweight Rating, Announces \$80 Price Target

Financial news for QURE dated on 2019-04-08: A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street

Financial news for QURE dated on 2019-04-08: uniQure Reports FDA Fast Track Designation For AMT-130 Gene Therapy For Treatment Of Huntington's Disease

Financial news for QURE dated on 2019-03-29: Benzinga's Top Upgrades, Downgrades For March 29, 2019

Financial news for QURE dated on 2019-03-29: Baird Initiates Coverage On uniQure with Outperform Rating, Announces \$85 Price Target

Financial news for QURE dated on 2019-03-27: 6 Gene Therapy M&A Targets On The Radar

Financial news for QURE dated on 2019-03-22: The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback

Financial news for QURE dated on 2019-03-15: CORRECTION: Wells Fargo Maintained Outperform Rating On uniQure, Raised Price Target From \$65 To \$90; Initial headline suggested the price target was lowered; this was incorrect

Financial news for QURE dated on 2019-03-15: Wells Fargo Maintains Outperform on uniQure, Raises Price Target to \$90

Financial news for QURE dated on 2019-03-12: The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Financial news for QURE dated on 2019-03-08: The Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings

Financial news for QURE dated on 2019-03-06: Shares of several biotech companies are trading lower after FDA commissioner Scott Gottlieb announced he will resign; he

pushed to spur the development of new drugs and with his absence, there is concern on future FDA approvals.

Financial news for QURE dated on 2019-02-28: uniQure BV Q3 EPS \$(0.59) Beats \$(0.62) Estimate, Sales \$3.148M Beat \$2.81M Estimate

Financial news for QURE dated on 2019-02-27: uniQure Highlights Presentation Of New Preclinical Data On AMT-130 At The CHDI's 14th Annual Huntington's Disease Therapeutics Conference

Financial news for QURE dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for QURE dated on 2019-02-26: 72 Biggest Movers From Yesterday

Financial news for QURE dated on 2019-02-25: Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Financial news for QURE dated on 2019-02-25: 42 Stocks Moving In Monday's Mid-Day Session

Financial news for QURE dated on 2019-02-25: Mid-Morning Market Update: Markets Open Higher; Roche To Acquire Spark Therapeutics For \$114.50/Share

Financial news for QURE dated on 2019-02-25: Cantor Fitzgerald Maintains Overweight on uniQure, Raises Price Target to \$81

Financial news for QURE dated on 2019-02-25: Shares of gene therapy companies are trading higher after Roche announced it would acquire Spark Therapeutics for \$114.50 per share in cash.

Financial news for QURE dated on 2019-02-25: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for QURE dated on 2019-02-11: 66 Biggest Movers From Friday

Financial news for QURE dated on 2019-02-08: 48 Stocks Moving In Friday's Mid-Day Session

Financial news for QURE dated on 2019-02-08: The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

Financial news for QURE dated on 2019-02-08: uniQure Offers Updated Clinical Data From Phase IIb Study Of AMT-061 In Patients With Hemophilia B

Financial news for QURE dated on 2019-02-04: uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B

Financial news for QURE dated on 2019-01-22: Unique Announces FDA Clearance Of Investigational New Drug Application For Amt-130 In Huntington's Disease

Financial news for QURE dated on 2018-12-31: Benzinga's Top Upgrades, Downgrades For December 31, 2018

Financial news for QURE dated on 2018-11-16: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Nov. 16, 2018

Financial news for QURE dated on 2018-11-16: B. Riley FBR Maintains Buy on uniQure, Raises Price Target to \$72

Financial news for QURE dated on 2018-11-16: 64 Biggest Movers From Yesterday

Financial news for QURE dated on 2018-11-15: Mid-Afternoon Market Update: Dow Up 240 Points; Unique Shares Spike Higher

Financial news for QURE dated on 2018-11-15: 45 Stocks Moving In Thursday's Mid-Day Session

Financial news for QURE dated on 2018-11-15: Mid-Day Market Update: Smart & Final Stores Rises Following Strong Q3 Earnings; Remark Holdings Shares Drop

Financial news for QURE dated on 2018-11-15: UniQure NV shares are up 49.3% after the company reported all hemophilia patients in its dose-combo study of AMT-061 achieved a positive response.

Financial news for QURE dated on 2018-11-15: Mid-Morning Market Update: Markets Open Lower; Walmart Profit Tops Expectations

Financial news for QURE dated on 2018-11-15: uniQure Offers Initial Top-Line Data

From Dose-Combo Study Of AMT-061 In Patients With Hemophilia B: 'All Patients Achieved and Sustained Therapeutic Factor IX Activity with a Mean FIX Level of 31%'

Financial news for QURE dated on 2018-11-06: uniQure BV Q3 EPS \$(0.59) Beats \$(0.62) Estimate, Sales \$3.148M Beat \$2.81M Estimate

Financial news for QURE dated on 2018-09-24: H.C. Wainwright Maintains Buy on uniQure, Raises Price Target to \$48

Financial news for QURE dated on 2018-09-24: uniQure Announces a Third Patient Treated in its Phase IIb Study of AMT-061

Financial news for QURE dated on 2018-09-06: Stocks Which Set New 52-Week High Yesterday, September 5th

Financial news for QURE dated on 2018-09-05: Stocks Which Set New 52-Week High Yesterday, September 4th

Financial news for QURE dated on 2018-09-05: The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results

Financial news for QURE dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for QURE dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for QURE dated on 2018-08-30: Stocks Which Set New 52-Week High Yesterday, August 29th

Financial news for QURE dated on 2018-08-30: The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration

Financial news for QURE dated on 2018-08-29: Stocks Which Set New 52-Week High Yesterday, August 28th

Financial news for QURE dated on 2018-08-29: The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent

Financial news for QURE dated on 2018-08-23: uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B, Expects Topline Data In Q4 2018

Financial news for QURE dated on 2018-08-08: uniQure Q2 EPS \$(0.57) Beats \$(0.61) Estimate, Sales \$3.1M Beat \$2.87M Estimate

Financial news for QURE dated on 2018-07-27: Benzinga's Top Upgrades, Downgrades For July 27, 2018

Financial news for QURE dated on 2018-07-27: Cantor Fitzgerald Initiates Coverage On uniQure with Overweight Rating, Announces \$58 Price Target

Financial news for QURE dated on 2018-07-17: 40 Biggest Movers From Yesterday

Financial news for QURE dated on 2018-06-29: 48 Biggest Movers From Yesterday

Financial news for QURE dated on 2018-06-28: 3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy

Financial news for QURE dated on 2018-06-28: B. Riley FBR Initiates Coverage On uniQure with Buy Rating, Announces \$50 Price Target

Financial news for QURE dated on 2018-06-28: uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B

Financial news for QURE dated on 2018-06-21: Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street

Financial news for QURE dated on 2018-06-14: uniQure Files For Potential Mixed Shelf Offering, No Size Disclosed

Financial news for QURE dated on 2018-06-12: 44 Biggest Movers From Yesterday

Financial news for QURE dated on 2018-05-29: uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy, Additional Issued Patent Covering Manufacturing Further Strengthens Intellectual Property Portfolio

Financial news for QURE dated on 2018-05-24: SunTrust Robinson Humphrey Initiates Coverage On uniQure with Buy Rating, Announces \$48 Price Target

Financial news for QURE dated on 2018-05-21: uniQure Presents Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies

Financial news for QURE dated on 2018-05-20: Uniqure Notches Bullish Initiation On Gene Therapy Prospects

Financial news for QURE dated on 2018-05-16: Wells Fargo Initiates Coverage On uniQure with Outperform Rating, Announces \$47 Price Target

Financial news for QURE dated on 2018-05-02: UniQure Prices 4.5M Share Offering @\$28.50/Share

Financial news for QURE dated on 2018-05-01: uniQure Announces 4M Common Share Offering

Financial news for QURE dated on 2018-04-30: uniQure Reports Q1 EPS \$(0.59) Beats \$(0.74) Est., Sales \$3.48M Beats \$2.82M Est.

Financial news for QURE dated on 2018-04-25: uniQure Offers Preclinical Data On AMT-130 In Huntington's Disease, Showed Single Intraparenchymal Administration Of AMT-130 In Striatum Resulted In Dose-Dependent, Sustained Reduction Of mHTT In Both Deep Structures Of Brain

Financial news for QURE dated on 2018-04-24: Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure

Financial news for QURE dated on 2018-04-10: 40 Biggest Movers From Yesterday

Financial news for QURE dated on 2018-04-09: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for QURE dated on 2018-03-20: Janney: Buy The Dip In Uniqure

Financial news for QURE dated on 2018-03-20: Janney On uniQure: 'Buy On Weakness'; Fair Value Target Raised From \$25 To \$30, AMT-130 For HD Added To Valuation

Financial news for QURE dated on 2018-03-14: uniQure Reports FY EPS \$(2.94) vs \$(2.88) Est., Sales \$13.11M vs \$12.64M Est.

Financial news for QURE dated on 2018-03-14: uniQure Reports FY17 EPS \$(2.94) vs \$(2.93) In Prior Year

Financial news for QURE dated on 2018-02-13: uniQure Spikes to High of \$22.59; Co Presenting Today at SunTrust 4th Annual Orphan Drug Day

Financial news for QURE dated on 2018-02-13: 33 Biggest Movers From Yesterday

Financial news for QURE dated on 2018-02-12: UPDATE: uniQure Shares Continue to Spike Higher; Co Also Presenting at Leerink Global Healthcare Conference on February 14, 15

Financial news for QURE dated on 2018-02-12: uniQure Spikes to High of \$20.46; Co to Present Tomorrow at SunTrust 4th Annual Orphan Drug Day, February 13, 2018 in New York City

Financial news for QURE dated on 2018-01-23: 38 Biggest Movers From Yesterday

Financial news for QURE dated on 2018-01-22: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for QURE dated on 2018-01-22: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for QURE dated on 2018-01-22: uniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntington's disease

Financial news for QURE dated on 2018-01-08: uniQure Shares Down 7% Mon.; Co. Earlier Outlined Near-Term Objectives: 'Pivotal Trial in Hemophilia B on Track to Begin in Q3 2018, with Initial AMT-061 Clinical Data by Year End'

Financial news for QURE dated on 2018-01-04: Janney Capital Initiates Coverage On uniQure with Buy Rating, Announces \$25.00 Price Target

Financial news for QURE dated on 2017-12-11: uniQure Reports Second Dose Cohort Demonstrated 89% Reduction in Spontaneous Bleeds, with No Confirmed Bleeds Reported

in Last 12 Mo.; Clinical Benefit Maintained in All Patients, with Durable Increases in FIX Clotting Activity At Up To 2 Years Follow Up

Financial news for QURE dated on 2017-12-09: uniQure Announces Presentation of Non-Clinical Data of AMT-061 at #ASH2017

Financial news for QURE dated on 2017-12-08: Uniqure Option Alert: Jan 19 \$17.5 Calls at the Ask: 2500 @ \$2.0 vs 141 OI; Ref=\$17.32

Financial news for QURE dated on 2017-12-07: uniQure Shares Up 11.67% On No Apparent News

Financial news for QURE dated on 2017-12-01: 25 Stocks Moving In Friday's Mid-Day Session

Financial news for QURE dated on 2017-12-01: Benzinga's Top Upgrades, Downgrades For December 1, 2017

Financial news for QURE dated on 2017-12-01: H.C. Wainwright Initiates Coverage On uniQure NV with Buy Rating, Announces \$28.00 Price Target

Financial news for QURE dated on 2017-11-07: uniQure Shares Spike Higher To Afternoon Highs As Leerink Mid-Day Comments Showed Raised Price Target To \$26

Financial news for QURE dated on 2017-11-07: Evercore ISI Group Initiates Coverage On uniQure NV with Outperform Rating, Announces \$22.00 Price Target

Financial news for QURE dated on 2017-11-03: uniQure 13G From Foresite Capital Fund Shows 5.5% Stake

Financial news for QURE dated on 2017-11-01: uniQure Reports Q3 EPS \$(0.40) vs \$(0.64) Est., Sales \$2.3M vs \$6.3M Est.

Financial news for QURE dated on 2017-10-25: uniQure Prices 5M Share Public Offering @\$18.25/Share

Financial news for QURE dated on 2017-10-24: Benzinga's Option Alert Recap From October 24

Financial news for QURE dated on 2017-10-24: 33 Stocks Moving In Tuesday's Mid-Day Session

Financial news for QURE dated on 2017-10-24: UniQure Option Alert: Nov 17 \$22.5 Calls Sweep (19) at the Bid: 601 @ \$0.7 vs 72 OI; Ref=\$19.05

Financial news for QURE dated on 2017-10-24: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for QURE dated on 2017-10-23: uniQure Reports Offering Of 5M Shares Of Common Stock

Financial news for QURE dated on 2017-10-23: Uniqure Shares Turn Positive Over Last Few Mins., Breaking Above \$19 Resistance Level; Stock Up 1.8% For Session, Flirting With \$20 Level

Financial news for QURE dated on 2017-10-23: 35 Biggest Movers From Friday

Financial news for QURE dated on 2017-10-20: There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials

Financial news for QURE dated on 2017-10-20: 32 Stocks Moving In Friday's Mid-Day Session

Financial news for QURE dated on 2017-10-20: Wall Street's M&A Chatter From October 19: Uniqure, Ulta, Sally Beauty, Tribune -Sinclair

Financial news for QURE dated on 2017-10-20: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for QURE dated on 2017-10-20: 38 Biggest Movers From Yesterday

Financial news for QURE dated on 2017-10-19: Mid-Afternoon Market Update: Crude Oil Down 1.25%; Alcobra Shares Spike Higher

Financial news for QURE dated on 2017-10-19: 32 Stocks Moving In Thursday's Mid-Day Session

Financial news for QURE dated on 2017-10-19: Mid-Day Market Update: Heritage-Crystal Clean Drops On Weak Q3 Results; Imprimis Pharmaceuticals Shares Surge



Financial news for QURE dated on 2017-10-19: Oppenheimer Out Positive On uniQure, Says Acquisition of AMT-061 Was Astute, Believes Product Has Potentially 6-7 Times The Well-Known Fix Expression Levels Of AMT-060; Believes It's A Potentially Significant Benefit To Hemophilia Patients

Financial news for QURE dated on 2017-10-19: uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX

Financial news for QURE dated on 2017-10-19: 38 Biggest Movers From Yesterday

Financial news for QURE dated on 2017-10-18: 32 Stocks Moving In Wednesday's Mid-Day Session

Financial news for QURE dated on 2017-10-18: UPDATE: uniQure Reports IND-Enabling Toxicology Study Initiated

Financial news for QURE dated on 2017-10-18: uniQure To Offer Preclinical Data On AMT-130 In Huntington's Disease At ESGCT Congress: Highlights 1-Time Administration Showed 'Survival Benefit and Functional Improvement of Huntington's Disease Symptoms in Preclinical Study'

Financial news for QURE dated on 2017-10-06: A Peek Into The Markets: U.S. Stock Futures Mostly Flat; All Eyes On Jobs Data

Financial news for QURE dated on 2017-10-06: uniQure Granted Orphan Drug Designation for AMT-130 by the FDA

Financial news for QURE dated on 2017-09-14: Companies Holding Shareholder Meetings Today Include: AMREP, Bovie Medical, Dorial LPG, Ellomay Capital, H&R Block, Interpace Diagnostics Group, Methode Electronics, NetApp, PhotoMedex, StealthGas, STRATA Skin Sciences, and uniQure

Financial news for QURE dated on 2017-08-28: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for QURE dated on 2017-08-08: uniQure Q2 EPS \$(0.83) vs \$(0.80) Est., Sales \$4.9M vs \$2.6M Est.

Financial news for QURE dated on 2017-08-07: uniQure Announces Scot McMillan COO

Financial news for QURE dated on 2017-07-31: uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate for Hemophilia B

Financial news for QURE dated on 2017-07-18: uniQure Granted Patent Protecting Insect Cell-Based AAV Manufacturing

Financial news for QURE dated on 2017-07-11: uniQure Says New Data Supports Expanding Eligibility of AAV5 to Hemophilia B Patients

Financial news for QURE dated on 2017-07-10: UPDATE: uniQure On AMT-060 Says, 'No Activation of T-Cell Responses or Loss of FIX Activity in Any Patient Up To 18 Months'

Financial news for QURE dated on 2017-07-10: UPDATE: uniQure On AMT-060 Says, 'Second-dose Cohort Demonstrates Dose Response Up to One Year, with 84% Reduction in Spontaneous Bleeds and All Patients Free of Prophylactic FIX Replacement Therapy'

Financial news for QURE dated on 2017-07-10: UPDATE: uniQure On AMT-060 Data, Says 'Clinical Benefit Maintained in All Patients, with FIX Activity Persisting At Up To 18 Months of Follow-Up'

Financial news for QURE dated on 2017-07-10: uniQure Issues Updated, Long-Term Data From Ongoing Phase I/II Trial Of AMT-060 In Patients with Severe Hemophilia B

Financial news for QURE dated on 2017-07-07: A Barrage Of Biotech Updates Expected At ISTH Meeting

Financial news for QURE dated on 2017-05-11: uniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates

Financial news for QURE dated on 2017-05-10: uniQure Offers New Data on AAV5 Vector: 'Strong Dose-Dependent Transduction in All Animals Tested Regardless of the Level of Anti-AAV5 Antibodies at Pre-Administration'

Financial news for QURE dated on 2017-05-10: uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates

Financial news for QURE dated on 2017-05-09: uniQure Q1 EPS \$(0.80) vs \$(0.66) Est, Sales \$3.32M vs \$6.32M Est

Financial news for QURE dated on 2017-04-25: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for QURE dated on 2017-04-25: uniQure Reports Received EMA Priority Medicines Designation for AMT-060 in Hemophilia B

Financial news for QURE dated on 2017-04-20: UPDATE: uniQure Says Sees Reducing Further Expenses Related to Product by ~\$2M Annually Beginning in 2018

Financial news for QURE dated on 2017-04-20: uniQure Says Will Not Seek Marketing Authorization Renewal for Glybera in Europe

Financial news for QURE dated on 2017-04-04: uniQure Publishes Data in Gene Therapy Demonstrating Wide Distribution of AAV5 in the Central Nervous System

Financial news for QURE dated on 2017-03-15: uniQure Q4 EPS \$(0.58) vs \$(0.59) Est, Sales \$25.1M vs \$5.8M Est

Financial news for QURE dated on 2017-01-30: 25 Stocks Moving In Monday's Pre-Market Session

Financial news for QURE dated on 2017-01-30: uniQure Reports FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B

Financial news for QURE dated on 2016-12-19: uniQure Announces Matthew Kapusta CEO, Previously Interim CEO

Financial news for QURE dated on 2016-12-05: UniQure Vs. Spark Therapeutics: One Has Better Timing, The Other Has Better Efficacy

Financial news for QURE dated on 2016-12-03: uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B at ASH 2016

Financial news for QURE dated on 2016-12-02: American Society Of Hematology Meeting Begins Dec. 3rd, Day 1 of 4

Financial news for QURE dated on 2016-11-22: 7 Biggest Price Target Changes For Tuesday

Financial news for QURE dated on 2016-11-22: uniQure Q3 EPS EUR 0.54, Revenue EUR 3.15M

Financial news for QURE dated on 2016-11-22: Jefferies Downgrades uniQure to Hold, Lowers Target to \$8.00

Financial news for QURE dated on 2016-11-16: PiperJaffray Downgrades uniQure N.V. - Ordinary Shares to Neutral

Financial news for QURE dated on 2016-11-15: uniQure Completes Strategic Review, Will Focus on Late-Stage Development of Hemophilia B

Financial news for QURE dated on 2016-10-11: Jefferies Gene Editing/Gene Therapy Summit Commences Today With Presenters Including bluebird bio, Audentes Therapeutics, Spark Therapeutics, Sangamo Biosciences, And uniQure

Financial news for QURE dated on 2016-09-22: uniQure Reports Resignation of CEO Daniel Soland; CFO Matthew Kapusta Named as Interim Replacement

Financial news for QURE dated on 2016-09-16: uniQure Receives NASDAQ Deficiency Letter Related to Board Composition

Financial news for QURE dated on 2016-08-25: uniQure Reports Q2 EPS \$(0.87) vs \$(0.89) Est., Total Sales \$1.615M

Financial news for QURE dated on 2016-08-04: Benzinga's Top Initiations

Financial news for QURE dated on 2016-08-04: H.C. Wainwright Assumes uniQure at Buy

Financial news for QURE dated on 2016-07-27: uniQure Says 4 Patient Remain Free of Prophylactic FIX Infusions, Achieving 82% Reduction in total FIX Usage

Financial news for QURE dated on 2016-07-11: uniQure Announces Oral Presentation of Updated Results for AMT-060 at WFH 2016 World Congress

Financial news for QURE dated on 2016-06-11: uniQure Announces Clinical Data from Ongoing Phase I/II Study in Hemophilia B Demonstrating 6 Months of Sustained Increases in Factor IX Activity

Financial news for QURE dated on 2016-05-31: UniQure Reports Q1 Loss/Share EUR(0.83); Revenue EUR3.902M

Financial news for QURE dated on 2016-05-09: uniQure Nominates Jake Kaye To Board, Proposes Corp. Governance Changes

Financial news for QURE dated on 2016-05-09: uniQure Presents Preclinical Data on AAV Re-Administration, Regulated Gene Expression and Total Brain Transduction at ASGCT

Financial news for QURE dated on 2016-03-22: uniQure Reports Preclinical PoC for Gene Therapy Approach in Huntington's Disease

Financial news for QURE dated on 2016-03-14: uniQure Announces First Patient Dosed in High-Dose Cohort in Phase I/II Hemophilia B Clinical Trial

Financial news for QURE dated on 2016-02-24: HC Wainwright Assumes Buy On uniQure N. V. With \$30 PT

Financial news for QURE dated on 2016-01-07: Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; UniQure Shares Gain Following Release Of Clinical Trial Data

Financial news for QURE dated on 2016-01-07: Shares Of Unique NV Surge Following Release Of Clinical Trial Data

Financial news for QURE dated on 2016-01-07: Benzinga's Volume Movers

Financial news for QURE dated on 2016-01-07: Benzinga's Top #PreMarket Gainers

Financial news for QURE dated on 2016-01-07: uniQure +21.4% Premarket @\$18.10; Co Announced Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial

Financial news for QURE dated on 2016-01-07: uniQure Announces Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial

Financial news for QURE dated on 2016-01-06: uniQure Announces Conference Call, Will Discuss Low-Dose Cohort In Hemophilia B Phase I/II Gene Therapy Clinical Trial

Financial news for QURE dated on 2015-12-18: Unique Announces Dan Soland CEO, Was Previously COO

Financial news for QURE dated on 2015-12-18: uniQure Names Dan Soland as CEO

Financial news for QURE dated on 2015-12-01: UPDATE: Chardan's Amusa Notes uniQure 'would not pursue regulatory approval for Glybera in the US, confirming a positive for us...'

Financial news for QURE dated on 2015-12-01: Chardan Capital Says Buy uniQure 'on the market's -17% reaction to old or expected news'; Reiterates Buy Rating, \$40 Target

Financial news for QURE dated on 2015-11-30: UPDATE: uniQure Reports Q3 Revs \$3.15M Vs Est \$2.80M

Financial news for QURE dated on 2015-11-30: uniQure Reports Q3 EPS EUR(0.67) Vs Est EUR\$(0.66)

Financial news for QURE dated on 2015-11-30: Earnings Scheduled For November 30, 2015

Financial news for QURE dated on 2015-10-06: Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Financial news for QURE dated on 2015-09-21: Morning Market Gainers

Financial news for QURE dated on 2015-09-21: Benzinga's Top #PreMarket Gainers

Financial news for QURE dated on 2015-09-21: uniQure +15% Following Saturday Announcement of Positive Topline Results from Phase I/II Trial in Sanfilippo B Syndrome Patients Using AAV5-Based Gene Therapy

Financial news for QURE dated on 2015-09-19: uniQure Announces Positive Topline Results from Phase I/II Trial in Sanfilippo B Syndrome Patients Using AAV5-Based Gene Therapy

Financial news for QURE dated on 2015-09-18: Benzinga's Volume Movers

Financial news for QURE dated on 2015-08-27: uniQure Reports Q2 Loss/Share EUR(0.87); Revenue EUR1.615M

Financial news for QURE dated on 2015-08-25: Market Panic Has Created 'Compelling' Opportunities In Biotech

Financial news for QURE dated on 2015-08-25: Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cempra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics

Financial news for QURE dated on 2015-08-10: uniQure Receives Additional \$53M from Bristol-Myers Squibb for Target Selection Payment and Additional Equity Investment

Financial news for QURE dated on 2015-08-07: Benzinga's Top Initiations

Financial news for QURE dated on 2015-08-07: WallachBeth Initiates Coverage on uniQure at Buy, Announces \$35.00 PT

Financial news for QURE dated on 2015-07-16: Roth Capital's Chattopadhyay Sees 'Compelling Entry Point' in Shares of uniQure

Financial news for QURE dated on 2015-07-15: Cowen Starts Unique At Outperform, Sees Hemophilia As 'Most Significant' Near-Term Catalyst

Financial news for QURE dated on 2015-07-15: Cowen & Company Initiates Coverage on uniQure at Outperform

Financial news for QURE dated on 2015-05-26: uniQure Report Closing of Strategic Partnership with Bristol-Myers Squibb to Develop Cardiovascular Disease Gene Therapies

Financial news for QURE dated on 2015-05-22: 2 Gene Therapy Stocks Oppenheimer Just Said Will 'Outperform'

Financial news for QURE dated on 2015-05-22: Benzinga's Top Initiations

Financial news for QURE dated on 2015-05-22: Oppenheimer Initiates Unique With Outperform

Financial news for QURE dated on 2015-05-22: Oppenheimer Initiates Coverage on uniQure at Outperform, Announces \$47.00 PT

Financial news for QURE dated on 2015-05-12: uniQure Reports Q1 Loss \$0.30 Vs Exp Loss \$0.31, Sales \$4.01M

Financial news for QURE dated on 2015-05-05: 6-K from uniQure Shows Committee for Advanced Therapies Has Requested Supplemental Info Related to Glybera, Co. Continues to Suggest Data of Glybera Supports Efficacy

Financial news for QURE dated on 2015-04-27: Adam Feuerstein @adamfeuerstein Tweet: From last night --> Gene Therapy Stocks on Watch Following Failure of \$CLDN Heart Failure Trial thestreet.com/story/13126476... \$BLUE \$QURE \$ONCE

Financial news for QURE dated on 2015-04-24: Benzinga's Top Initiations

Financial news for QURE dated on 2015-04-24: Chardan Capital Initiates UniQure At Buy

Financial news for QURE dated on 2015-04-24: Chardan Capital Initiates Coverage on uniQure at Buy, Announces \$40.00 PT

Financial news for QURE dated on 2015-04-22: BMO Capital Initiates Coverage on uniQure at Outperform, Announces \$49.00 PT

Financial news for QURE dated on 2015-04-13: Benzinga's Volume Movers

Financial news for QURE dated on 2015-04-10: Morning Market Losers

Financial news for QURE dated on 2015-04-10: Benzinga's Top #PreMarket Losers

Financial news for QURE dated on 2015-04-10: uniQure Prices 3M Share Offering @\$29.50/Share

Financial news for QURE dated on 2015-04-09: Morning Market Losers

Financial news for QURE dated on 2015-04-09: Benzinga's Top #PreMarket Losers

Financial news for QURE dated on 2015-04-07: uniQure Announces Launch of Follow-on Public Offering, 3M Shares

Financial news for QURE dated on 2015-04-06: Benzinga's Volume Movers

Financial news for QURE dated on 2015-04-06: Stocks Hitting 52-Week Highs

Financial news for QURE dated on 2015-04-06: Morning Market Gainers

Financial news for QURE dated on 2015-04-06: UPDATE: uniQure Share Rise 53% Premarket Following Announcement of Deal With Bristol-Myers Squibb

Financial news for QURE dated on 2015-04-06: uniQure Reports Q4 Earnings from Licensing, Collaboration Sales EUR1.5M, FY14 Loss of EUR2.16/Share

Financial news for QURE dated on 2015-04-06: Benzinga's Top #PreMarket Gainers

Financial news for QURE dated on 2015-04-06: uniQure Share Rise 14% Premarket on Light Trading, Following Announcement of Deal With Bristol-Myers Squibb,

Financial news for QURE dated on 2015-04-06: UPDATE: uniQure to Receive \$50M Upfront Payment at Close of Transaction; Bristol-Myers-Squibb to Acquire Additional 5% Ownership Before December 31, 2015 at 10% Premium

Financial news for QURE dated on 2015-04-06: Bristol-Myers Squibb, uniQure Report Deal Providing Bristol Exclusive Access to uniQure's Gene Therapy Technology Platform for Multiple Targets in CV Diseases

Financial news for QURE dated on 2015-03-12: uniQure N.V Reports FY 2014 EPS \$3.28, Sales \$28.4M, No Estimates Available

Financial news for QURE dated on 2015-03-11: 18 Biotech Stocks These Wall Street Analysts Are Tracking

Financial news for QURE dated on 2015-03-03: Filing from uniQure Shows Registration for \$250M Mixed Securities Shelf Offering

Financial news for QURE dated on 2015-01-20: Why Drug Pricing Could Bring Volatility To The Biotech Sector This Year

Financial news for QURE dated on 2015-01-14: Treeway Announces License, Collaboration Agreement With uniQure

Financial news for QURE dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for QURE dated on 2014-08-11: uniQure Announces Acquisition of Cardiology Gene Therapy For EU3 Million

Financial news for QURE dated on 2014-08-04: Unique Says Expects to Launch Glybera in Q4 2014/Q1 2015

Financial news for QURE dated on 2014-07-01: uniQure Closes on Additional \$10M Venture Loan from Hercules Capital

Financial news for QURE dated on 2014-06-03: uniQure Six Year FOLlow-Up Results for Glybera Positive, 40-50% Lower Post Treatment Pancreatitis Events

Financial news for QURE dated on 2014-06-03: uniQure Offers Analysis of Six-Year Follow-Up Data for Glybera

Financial news for QURE dated on 2014-05-29: uniQure, Medison Sign Glybera Distribution Agreement for Israel

Financial news for QURE dated on 2014-05-27: uniQure Announces Successful Transfection of Liver Cells with AAV5 and Strong Safety Data from Acute Intermittent Porphyria Clinical Trial

Financial news for QURE dated on 2014-04-09: UPDATE: uniQure Initiates Search for New COO

Financial news for QURE dated on 2014-04-09: uniQure Names Eric Goossens as New COO

Financial news for QURE dated on 2014-03-03: Piper Jaffray Initiates Coverage on uniQure BV at Overweight, Announces \$35.00 PT

Financial news for QURE dated on 2014-03-03: Leerink Swann Initiates Coverage on uniQure BV at Outperform, Announces \$25.00 PT

Financial news for QURE dated on 2014-03-03: Jefferies Initiates Coverage on uniQure BV at Buy, Announces \$24.00 PT

Financial news for QURE dated on 2014-02-05: Shares of uniQure Open for Trade at \$17

After Price at \$17/Share

Financial news for QURE dated on 2014-02-05: Waiting on IPO Opens for:

Financial news for QURE dated on 2014-01-24: uniQure Sets IPO of 4.6M Shares at \$13-15/Share

Financial news for QURE dated on 2014-01-02: Unique BV Files \$75M IPO, Expects to List on NASDAQ Under 'QURE'